UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR LakeShore Biopharma Co., Ltd (Exact name of Registrant as ...

Core Viewpoint - YS Biopharma Co., Ltd. is changing its legal name to LakeShore Biopharma Co., Ltd. to enhance its global market positioning and brand image [1] Group 1: Company Name Change - The name change to LakeShore Biopharma is part of the company's strategy to expand its market reach [1] - The trading symbol will change from "YS" to "LSB" and from "YSBPW" to "LSBPW" effective May 28, 2024 [1] - The name change will not affect shareholders' rights or the company's operations and financial position [1] Group 2: Company Overview - LakeShore Biopharma focuses on discovering, developing, manufacturing, and delivering vaccines and therapeutic biologics for infectious diseases and cancer [2] - The company has developed a proprietary PIKA® immunomodulating technology platform targeting various viral infections [2] - LakeShore Biopharma operates in multiple countries including China, the United States, Singapore, and the Philippines [2]

GAITHERSBURG, Md., May 21, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced the results of its extraordinary general meeting (the "EGM") held on May 21, 2024 in Hong Kong. Each of the following resolutions was passed at the EGM: 1. As a special resolution that ...

GAITHERSBURG, Md., May 7, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it will hold an Extraordinary General Meeting of the Company (the "EGM") at the 35th Floor, Two Exchange Square, 8 Connaught Place, Central, Hong Kong, at 9:00 a.m. on May 21, 2024 ...

Financial Data and Key Metrics Changes - Total revenue for the first nine months of fiscal year 2024 was RMB 438.1 million, a year-over-year decline of 24.6% compared to RMB 581.2 million in the same period of fiscal 2023 [7][20] - Gross profit was RMB 351.7 million, with a gross margin of 80.3%, compared to RMB 449.0 million in the previous year [20][21] - The net loss for the period was RMB 252.3 million, compared to a net loss of RMB 64.2 million in the comparable period of 2023 [22] Business Line Data and Key Metrics Changes - The company experienced a decline in product sales during the first nine months but expects to return to a growth trajectory with double-digit year-over-year growth in product sales for the three-month period ending March 31, 2024 [6][20] - The YSJA rabies vaccine has sold over 25.6 million doses to approximately 1,746 CDC customers, representing over 6% of CDC customers in China since its launch [7][10] Market Data and Key Metrics Changes - The company has maintained its leadership position in the rabies vaccine market in China despite previous supply chain disruptions [5][6] - The sales network has expanded to cover 30 out of 31 province-level CDCs in China, enhancing market presence [10] Company Strategy and Development Direction - The company has initiated a series of operational enhancements, including improved supply chain management and cost controls, to fortify its foundation for future growth [8][9] - There is a strategic focus on advancing the product pipeline, particularly the PIKA rabies vaccine and PIKA HBV 002 vaccine, with plans for commercialization [12][15] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about returning to a growth trajectory and expects product revenue to increase at a double-digit rate in fiscal year 2025 [6][23] - The company is addressing past production issues and is focused on operational efficiency and inventory management to meet market demand [9][10] Other Important Information - The company has implemented measures to enhance internal controls and governance, including changes to the board of directors and senior management [8] - The interim results of the PIKA rabies vaccine Phase III clinical study indicate it has met primary endpoints and shows potential for a best-in-class profile [12][17] Q&A Session Summary Question: Overview of the timeline for the registration and commercialization of the PIKA rabies vaccine - Management indicated that the final report for the Phase III trial is being prepared, with plans to apply for conditional approval in various countries. Marketing authorization could take around one to two years [27][29] Question: Update on the development status of other drugs in the portfolio - The company plans to start the Phase 1 study for the chronic hepatitis B vaccine in May or June, with a focus on developing a treatment that could offer a single regimen compared to current lifelong antiviral medications [31][33]

Core Viewpoint - YS Biopharma Co., Ltd. is set to release its financial results for the first nine months of the fiscal year ending March 31, 2024, on April 19, 2024, before the U.S. market opens [1] Company Overview - YS Biopharma is a global biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer [4] - The company has developed a proprietary PIKA® immunomodulating technology platform and a series of biologics aimed at improving vaccines for Rabies, Coronavirus, Hepatitis B, Influenza, and Shingles [4] - YS Biopharma operates in multiple countries including China, the United States, Singapore, and the Philippines, and is led by a management team with extensive local and global experience in the biopharmaceutical industry [4] Earnings Conference Call - The management will hold an earnings conference call on April 19, 2024, at 8:00 A.M. Eastern Time to discuss the financial results [1] - Participants can access the call through various toll-free numbers provided for the United States, international, Mainland China, Canada, and Hong Kong [2] - A replay of the call will be available until April 26, 2024, along with a live and archived webcast on the company's investor relations website [3]

GAITHERSBURG, Md., April 9, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced positive interim results from the ongoing Phase 3 clinical trial (the "Phase 3 Trial" or the "Trial") of its next-generation PIKA Rabies Vaccine. The interim results indicate that the ...

GAITHERSBURG, Md., Feb. 22, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced the results of its extraordinary general meeting (the "EGM") held on February 22, 2024 in Hong Kong. The Company's shareholders voted in favor of each of the following resolutions: Re ...

GAITHERSBURG, Md., Feb. 16, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced the results of its extraordinary general meeting (the "EGM") held on February 16, 2024 in Seattle, United States. The Company's shareholders voted against each of the following resolu ...